Impact of combined fixed-dose formulations in Helicobacter pylori eradication on incidence rate of gastric cancer in Ukraine from 2014 to 2021

Авторы

DOI:

https://doi.org/10.26641/2307-0404.2025.1.325466

Ключевые слова:

Helicobacter pylori, eradication, gastric cancer, Ukraine

Аннотация

A worldwide decrease in the incidence of gastric cancer and its most common form, adenocarcinoma, has long been observed. Helicobacter pylori (H. pylori) is a causative carcinogen for gastric adenocarcinoma. Triple and quadruple regimens for H. pylori eradication have been well identified and established. Aims of the research: this article aims to evaluate trends in the administration of combined drug therapy for H. pylori eradication and how this can impact gastric cancer rates in Ukraine.Defined daily doses (DDD) of the combined drugs for H. pylori eradication (years 2014-2020), gastric cancer, and gastric adenocarcinoma incidence rates in Ukraine from 2014 to 2021 were calculated and analyzed annually per 100,000 of inhabitants. The number of DDDs of the combined drugs used in H. pylori eradication increased by 27.28% (p<0.0001). The incidence of gastric cancer decreased by 26.56% (p<0.0001) from 2014 to 2021. Gastric adeno­carcinoma was the most common form of gastric cancer comprising 94.56% (93.04–96.56%, 95% CI) of all cases. In Ukraine, the consumption of combined drugs for H. pylori eradication increased from 2014 to 2020, while the incidence of gastric cancer and gastric adenocarcinoma decreased from 2014 to 2021. Gastric adenocarcinoma is the most common form of gastric cancer in Ukraine. Use of these drugs might contribute to the decrease in gastric cancer incidence rate. These trends reflect global patterns.

Библиографические ссылки

Waldum H, Fossmark R. Gastritis, Gastric Polyps and Gastric Cancer. International Journal of Molecular Sciences. 2021 Jun 18;22(12):6548. doi: https://doi.org/10.3390/ijms22126548

Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric Cancer: Descriptive Epide-miology, Risk Factors, Screening, and Prevention. Cancer Epidemiology Biomarkers & Prevention. 2014;23(5):700-13. doi: https://doi.org/10.1158/1055-9965.EPI-13-1057

Malfertheiner P, Megraud F, O’Morain CA, Gis-bert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. doi: https://doi.org/10.1136/gutjnl-2016-312288

[Ministry of Health of Ukraine. State Register of Medicinal Products of Ukraine. Information fund]. [Internet]. [cited 2024 Dec 17]. Ukrainian.

Available from: www.drlz.com.ua

Malakhov K. Insight into the Digital Health System of Ukraine (eHealth): Trends, Definitions, Standards, and Legislative Revisions. International Journal of Telerehabilitation. 2023 Dec 12;15(2):e6599. doi: https://doi.org/10.5195/ijt.2023.6599

Lenz W. A short history of thalidomide embryopathy. Teratology. 1988 Sep;38(3):203-15. doi: https://doi.org/10.1002/tera.1420380303

PharmXplorer [Internet]. [cited 2024 Dec 17]. Available from: https://pharmxplorer.com.ua

Hollingworth S, Kairuz T. Measuring Medicine Use: Applying ATC/DDD Methodology to Real-World Data. Pharmacy. 2021 Mar 17;9(1):60. doi: https://doi.org/10.3390/pharmacy9010060

[National Cancer Registry of Ukraine. Short description of the database. Cancer in Ukraine. Ukrainian cancer registry statistics, bulletin of national cancer registry of Ukraine – No. 17-24]. [Internet]. [cited 2024 Dec 17]. Ukrainian. Available from: www.ncru.inf.ua

Chicco D, Warrens MJ, Jurman G. The coefficient of determination R-squared is more informative than SMAPE, MAE, MAPE, MSE and RMSE in regression analysis evaluation. PeerJ Computer Science. 2021 Jul 5;7(5):e623. doi: https://doi.org/10.7717/peerj-cs.623

Bramlage P, Schmidt S, Sims H. Fixed-dose vs free-dose combinations for the management of hyper-tension-An analysis of 81 958 patients. The Journal of Clinical Hypertension. 2018 Feb 19;20(4):705-15. doi: https://doi.org/10.1111/jch.13240

Helicobacter Pylori Infections Market: Key Companies, Therapies [Internet]. [cited 2024 Dec 17]. Available from: https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market

Yan L, Chen Y, Chen F, Tao T, Hu Z, Wang J, et al. Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a Randomized Controlled Trial with 26.5 years of follow-up. Gastro-enterology. 2022 Jul;163(1):154-162.e3. doi: https://doi.org/10.1053/j.gastro.2022.03.039

Weltermann T, Schulz C, Macke L. Effect of frequently prescribed drugs on gastric cancer risk. Best Practice & Research Clinical Gastroenterology. 2021 Mar;50-51:101741. doi: https://doi.org/10.1016/j.bpg.2021.101741

Baig MA, Bazarbashi MS, AlDakhil H, Baig SM. The Journey of Clinical Registries Through Various Phases of the Digital Age: A Technical Perspective. Studies in Health Technology and Informatics. 2022 Jan 14;289:345-8. doi: https://doi.org/10.3233/SHTI210930

Загрузки

Опубликован

2025-03-28

Как цитировать

1.
Protas Y, Makarenko O, Duka R. Impact of combined fixed-dose formulations in Helicobacter pylori eradication on incidence rate of gastric cancer in Ukraine from 2014 to 2021. Med. perspekt. [Интернет]. 28 март 2025 г. [цитируется по 5 декабрь 2025 г.];30(1):202-5. доступно на: https://journals.uran.ua/index.php/2307-0404/article/view/325466

Выпуск

Раздел

SOCIAL MEDICINE